Compare Stocks

3 / 10
Try these comparisons:

Stock Comparison

PHG vs SYK vs BSX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PHG
Koninklijke Philips N.V.

Medical - Devices

HealthcareNYSE • NL
Market Cap$25.90B
5Y Perf.-34.0%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$111.96B
5Y Perf.+49.4%
BSX
Boston Scientific Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$83.23B
5Y Perf.+47.4%

PHG vs SYK vs BSX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PHG logoPHG
SYK logoSYK
BSX logoBSX
IndustryMedical - DevicesMedical - DevicesMedical - Devices
Market Cap$25.90B$111.96B$83.23B
Revenue (TTM)$17.83B$25.12B$20.07B
Net Income (TTM)$895M$3.25B$2.89B
Gross Margin45.2%63.5%69.0%
Operating Margin8.0%22.4%19.8%
Forward P/E17.6x19.5x16.6x
Total Debt$8.09B$14.86B$12.42B
Cash & Equiv.$2.79B$4.01B$2.04B

PHG vs SYK vs BSXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PHG
SYK
BSX
StockMay 20May 26Return
Koninklijke Philips… (PHG)10066.0-34.0%
Stryker Corporation (SYK)100149.4+49.4%
Boston Scientific C… (BSX)100147.4+47.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: PHG vs SYK vs BSX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BSX leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Koninklijke Philips N.V. is the stronger pick specifically for dividend income and shareholder returns and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PHG
Koninklijke Philips N.V.
The Income Pick

PHG is the clearest fit if your priority is income & stability.

  • Dividend streak 1 yrs, beta 1.12, yield 1.5%
  • 1.5% yield, 1-year raise streak, vs SYK's 1.1%, (1 stock pays no dividend)
  • +17.0% vs BSX's -46.2%
Best for: income & stability
SYK
Stryker Corporation
The Long-Run Compounder

SYK is the clearest fit if your priority is long-term compounding and defensive.

  • 185.6% 10Y total return vs BSX's 154.2%
  • Beta 0.55, yield 1.1%, current ratio 1.89x
  • 6.9% ROA vs PHG's 3.4%, ROIC 11.4% vs 6.4%
Best for: long-term compounding and defensive
BSX
Boston Scientific Corporation
The Growth Play

BSX carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.

  • Rev growth 19.9%, EPS growth 55.2%, 3Y rev CAGR 16.5%
  • Lower volatility, beta 0.34, Low D/E 50.7%, current ratio 1.62x
  • 19.9% revenue growth vs PHG's -1.0%
Best for: growth exposure and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthBSX logoBSX19.9% revenue growth vs PHG's -1.0%
ValueBSX logoBSXLower P/E (16.6x vs 19.5x)
Quality / MarginsBSX logoBSX14.4% margin vs PHG's 5.0%
Stability / SafetyBSX logoBSXBeta 0.34 vs PHG's 1.12, lower leverage
DividendsPHG logoPHG1.5% yield, 1-year raise streak, vs SYK's 1.1%, (1 stock pays no dividend)
Momentum (1Y)PHG logoPHG+17.0% vs BSX's -46.2%
Efficiency (ROA)SYK logoSYK6.9% ROA vs PHG's 3.4%, ROIC 11.4% vs 6.4%

PHG vs SYK vs BSX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PHGKoninklijke Philips N.V.

Segment breakdown not available.

SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B
BSXBoston Scientific Corporation
FY 2025
Cardiovascular
66.0%$13.3B
MedSurg
34.0%$6.8B

PHG vs SYK vs BSX — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPHGLAGGINGBSX

Income & Cash Flow (Last 12 Months)

BSX leads this category, winning 4 of 6 comparable metrics.

SYK and PHG operate at a comparable scale, with $25.1B and $17.8B in trailing revenue. BSX is the more profitable business, keeping 14.4% of every revenue dollar as net income compared to PHG's 5.0%. On growth, BSX holds the edge at +15.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…
RevenueTrailing 12 months$17.8B$25.1B$20.1B
EBITDAEarnings before interest/tax$2.5B$6.3B$4.7B
Net IncomeAfter-tax profit$895M$3.2B$2.9B
Free Cash FlowCash after capex$755M$4.3B$3.6B
Gross MarginGross profit ÷ Revenue+45.2%+63.5%+69.0%
Operating MarginEBIT ÷ Revenue+8.0%+22.4%+19.8%
Net MarginNet income ÷ Revenue+5.0%+12.9%+14.4%
FCF MarginFCF ÷ Revenue+4.2%+17.1%+18.1%
Rev. Growth (YoY)Latest quarter vs prior year+1.1%+11.4%+15.9%
EPS Growth (YoY)Latest quarter vs prior year+2.1%+56.0%+18.5%
BSX leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

PHG leads this category, winning 4 of 6 comparable metrics.

At 24.9x trailing earnings, PHG trades at a 28% valuation discount to SYK's 34.8x P/E. On an enterprise value basis, PHG's 10.7x EV/EBITDA is more attractive than BSX's 25.1x.

MetricPHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…
Market CapShares × price$25.9B$112.0B$83.2B
Enterprise ValueMkt cap + debt − cash$32.1B$122.8B$93.6B
Trailing P/EPrice ÷ TTM EPS24.95x34.80x28.87x
Forward P/EPrice ÷ next-FY EPS est.17.59x19.49x16.58x
PEG RatioP/E ÷ EPS growth rate2.34x
EV / EBITDAEnterprise value multiple10.73x20.19x25.07x
Price / SalesMarket cap ÷ Revenue1.24x4.46x4.15x
Price / BookPrice ÷ Book value/share2.03x4.98x3.42x
Price / FCFMarket cap ÷ FCF24.72x26.14x22.75x
PHG leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

SYK leads this category, winning 4 of 9 comparable metrics.

SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $8 for PHG. BSX carries lower financial leverage with a 0.51x debt-to-equity ratio, signaling a more conservative balance sheet compared to PHG's 0.74x. On the Piotroski fundamental quality scale (0–9), PHG scores 7/9 vs SYK's 6/9, reflecting strong financial health.

MetricPHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…
ROE (TTM)Return on equity+8.2%+15.0%+12.4%
ROA (TTM)Return on assets+3.4%+6.9%+6.9%
ROICReturn on invested capital+6.4%+11.4%+8.8%
ROCEReturn on capital employed+7.1%+13.0%+11.1%
Piotroski ScoreFundamental quality 0–9767
Debt / EquityFinancial leverage0.74x0.66x0.51x
Net DebtTotal debt minus cash$5.3B$10.8B$10.4B
Cash & Equiv.Liquid assets$2.8B$4.0B$2.0B
Total DebtShort + long-term debt$8.1B$14.9B$12.4B
Interest CoverageEBIT ÷ Interest expense4.34x6.72x11.03x
SYK leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

PHG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in BSX five years ago would be worth $13,011 today (with dividends reinvested), compared to $5,814 for PHG. Over the past 12 months, PHG leads with a +17.0% total return vs BSX's -46.2%. The 3-year compound annual growth rate (CAGR) favors PHG at 11.6% vs SYK's 1.6% — a key indicator of consistent wealth creation.

MetricPHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…
YTD ReturnYear-to-date+0.6%-15.8%-40.9%
1-Year ReturnPast 12 months+17.0%-21.7%-46.2%
3-Year ReturnCumulative with dividends+39.2%+4.8%+5.4%
5-Year ReturnCumulative with dividends-41.9%+21.1%+30.1%
10-Year ReturnCumulative with dividends+47.9%+185.6%+154.2%
CAGR (3Y)Annualised 3-year return+11.6%+1.6%+1.8%
PHG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — PHG and BSX each lead in 1 of 2 comparable metrics.

BSX is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than PHG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PHG currently trades 81.4% from its 52-week high vs BSX's 51.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…
Beta (5Y)Sensitivity to S&P 5001.12x0.55x0.34x
52-Week HighHighest price in past year$33.44$404.87$109.50
52-Week LowLowest price in past year$21.95$289.91$54.98
% of 52W HighCurrent price vs 52-week peak+81.4%+72.2%+51.1%
RSI (14)Momentum oscillator 0–10040.525.433.1
Avg Volume (50D)Average daily shares traded1.0M2.0M15.3M
Evenly matched — PHG and BSX each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PHG and SYK each lead in 1 of 2 comparable metrics.

Analyst consensus: PHG as "Hold", SYK as "Buy", BSX as "Buy". Consensus price targets imply 63.1% upside for BSX (target: $91) vs 38.1% for SYK (target: $404). For income investors, PHG offers the higher dividend yield at 1.47% vs SYK's 1.15%.

MetricPHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…
Analyst RatingConsensus buy/hold/sellHoldBuyBuy
Price TargetConsensus 12-month target$403.69$91.33
# AnalystsCovering analysts225043
Dividend YieldAnnual dividend ÷ price+1.5%+1.1%
Dividend StreakConsecutive years of raises1340
Dividend / ShareAnnual DPS$0.34$3.36
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%
Evenly matched — PHG and SYK each lead in 1 of 2 comparable metrics.
Key Takeaway

PHG leads in 2 of 6 categories (Valuation Metrics, Total Returns). BSX leads in 1 (Income & Cash Flow). 2 tied.

Best OverallKoninklijke Philips N.V. (PHG)Leads 2 of 6 categories
Loading custom metrics...

PHG vs SYK vs BSX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PHG or SYK or BSX a better buy right now?

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus -1. 0% for Koninklijke Philips N. V. (PHG). Koninklijke Philips N. V. (PHG) offers the better valuation at 24. 9x trailing P/E (17. 6x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PHG or SYK or BSX?

On trailing P/E, Koninklijke Philips N.

V. (PHG) is the cheapest at 24. 9x versus Stryker Corporation at 34. 8x. On forward P/E, Boston Scientific Corporation is actually cheaper at 16. 6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — PHG or SYK or BSX?

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +30.

1%, compared to -41. 9% for Koninklijke Philips N. V. (PHG). Over 10 years, the gap is even starker: SYK returned +185. 6% versus PHG's +47. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PHG or SYK or BSX?

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus Koninklijke Philips N. V. 's 1. 12β — meaning PHG is approximately 225% more volatile than BSX relative to the S&P 500. On balance sheet safety, Boston Scientific Corporation (BSX) carries a lower debt/equity ratio of 51% versus 74% for Koninklijke Philips N. V. — giving it more financial flexibility in a downturn.

05

Which is growing faster — PHG or SYK or BSX?

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus -1. 0% for Koninklijke Philips N. V. (PHG). On earnings-per-share growth, the picture is similar: Koninklijke Philips N. V. grew EPS 224. 0% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PHG or SYK or BSX?

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus 5. 0% for Koninklijke Philips N. V. — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus 8. 0% for PHG. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PHG or SYK or BSX more undervalued right now?

On forward earnings alone, Boston Scientific Corporation (BSX) trades at 16.

6x forward P/E versus 19. 5x for Stryker Corporation — 2. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 63. 1% to $91. 33.

08

Which pays a better dividend — PHG or SYK or BSX?

In this comparison, PHG (1.

5% yield), SYK (1. 1% yield) pay a dividend. BSX does not pay a meaningful dividend and should not be held primarily for income.

09

Is PHG or SYK or BSX better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +185. 6% 10Y return). Both have compounded well over 10 years (SYK: +185. 6%, PHG: +47. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PHG and SYK and BSX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PHG is a mid-cap quality compounder stock; SYK is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock. PHG, SYK pay a dividend while BSX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

PHG

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

BSX

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 8%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PHG and SYK and BSX on the metrics below

Revenue Growth>
%
(PHG: 1.1% · SYK: 11.4%)
Net Margin>
%
(PHG: 5.0% · SYK: 12.9%)
P/E Ratio<
x
(PHG: 24.9x · SYK: 34.8x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.